Skip to main content

Advertisement

SpringerLink
Log in

Rituximab zur Therapie des Felty-Syndroms

Rituximab for treatment of Felty’s syndrome

  • Kasuistiken
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Das Felty-Syndrom ist eine seltene Verlaufsform einer schweren seropositiven rheumatoiden Arthrits mit Neutropenie und Splenomegalie. Die Therapie ist schwierig und die Prognose bei erheblichem Infektionsrisiko ungünstig. Es wird über einen Patienten mit therapierefraktärer Erkrankung berichtet, bei dem unter Rituximab eine anhaltende Normalisierung der Neutropenie eintrat. Wiederholte Infusionszyklen waren zum Erreichen und Erhalt der Remission erforderlich.

Abstract

Felty’s syndrome is a rare variant of severe seropositive rheumatoid arthritis with neutropenia and splenomegaly. It is difficult to treat and associated with a poor prognosis due to the substantial risk of infections. This article presents the case of a patient with refractory disease who responded to rituximab with permanent normalization of neutrophil counts. Repeated infusions were necessary to induce and maintain remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Balint GP, Balint PV (2004) Felty’s syndrome. Best Pract Res Clin Rheumatol 18:631–645

    Article  PubMed  Google Scholar 

  2. Ghavami A, Genevay S, Fulpius T, Gabay C (2005) Etanercept in treatment of Felty’s syndrome. Ann Rheum Dis 64:1090–1091

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Hellmich B, Csernok E, Schatz H et al (2002) Autoantibodies against granulocyte colony-stimulating factor in Felty’s syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 46:2384–2391

    Article  CAS  PubMed  Google Scholar 

  4. Liu X, Loughran TP Jr (2011) The spectrum of large granular lymphocyte leukemia and Felty’s syndrome. Curr Opin Hematol 18:254–259

    Article  CAS  PubMed  Google Scholar 

  5. Mahévas M, Audia S, De Lastours V et al (2007) Neutropenia in Felty’s syndrome successfully treated with hydroxychloroquine. Haematologica 92:e78–e79

    Article  PubMed  Google Scholar 

  6. Narváez J, Domingo-Domenech E, Gómez-Vaquero C et al (2012) Biological agents in the management of Felty’s syndrome: a systematic review. Semin Arthritis Rheum 41:658–668

    Article  PubMed  Google Scholar 

  7. Rubbert-Roth A, Tak PP, Zerbini C et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683–1693

    Google Scholar 

  8. Salama A, Schneider U, Dörner T (2008) Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis 67:894–895

    Article  CAS  PubMed  Google Scholar 

  9. Sordet C, Gottenberg JE, Hellmich B et al (2005) Lack of efficacy of rituximab in Felty’s syndrome. Ann Rheum Dis 64:332–333

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Wassenberg S, Herborn G, Rau R (1998) Methotrexate treatment in Felty’s syndrome. Br J Rheumatol 37:908–911

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. P. Willeke u. A. Jacobi erhielten von der Firma Roche Vortragshonorare. H. Becker, H. Appel, T. Fassbinder und D. Heitzmann geben an, dass kein Interessenkonflikt bestehen. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Sektion für Rheumatologie und klinische Immunologie, Medizinische Klinik D, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland

    H. Becker, T. Fassbinder, D. Heitzmann, P. Willeke & A.M. Jacobi

  2. Dialysezentrum Hamm, Hamm, Deutschland

    H. Appel

Authors
  1. H. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Appel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Fassbinder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Heitzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Willeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A.M. Jacobi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Becker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becker, H., Appel, H., Fassbinder, T. et al. Rituximab zur Therapie des Felty-Syndroms. Z. Rheumatol. 73, 465–468 (2014). https://doi.org/10.1007/s00393-014-1380-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1380-5

Schlüsselwörter

Keywords

Search

Navigation